Rational development of prophylactic HIV vaccines based on structural and regulatory proteins

Vaccine

Volumn 20, Issue 3-4, 2001, Pages 304-321

  Mooij, Petra ^a   Heeney, Jonathan Luke ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

HIV; Immune correlates; Multicomponent; Vaccine development

Indexed keywords

CHEMOKINE; CYTOKINE; DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; RECOMBINANT PROTEIN; REGULATOR PROTEIN; STRUCTURAL PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VIRUS VECTOR;

BIOTECHNOLOGY; CLINICAL TRIAL; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AIDS VACCINES; GENETIC VECTORS; HIV; HUMANS; IMMUNITY, MUCOSAL; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 0035851345     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00373-5     Document Type: Review

References (217)

1. Genetic diversity of HIV-1: The moving target
2. Recombination in HIV-1
3. Pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
4. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG
5. Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy
6. Accelerating the development and future availability of HIV-1 vaccines: Why, when, where, and how?
7. CD4+ T cells are required to sustain CD8+ cytotoxic T cell responses during chronic viral infection
8. Enhanced establishment of a virus carrier state in adult CD4+ T cell-deficient mice
9. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs
10. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
11. Association between virus-specific cytotoxic T lymphocyte and helper responses in human immunodeficiency virus type 1 infection
12. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
13. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralising humoral response
14. Reservoirs for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
15. Repression of MHC class I gene promoter activity by two-exon Tat of HIV
16. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
17. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
18. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules
19. The selective down-regulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells
20. HIV-1 Nef blocks transport of MHC class I molecules to the cell surface via a PI 3-kinase-dependent pathway
21. Nef-induced CD4 down-regulation: A diacidic sequence in human immunodeficiency virus type 1 Nef does not function as a protein sorting motif through direct binding to beta-COP
22. HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes
23. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules
24. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes
25. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4
26. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses
27. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
28. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection
29. Frequent detection of escape from cytotoxic T lymphocyte recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: The ariel project for the prevention of transmission of HIV from mother to infant
30. Kinetics of antiviral activity by human immunodeficiency virus type 1: Specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro
31. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
32. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viremia
33. Virus-specific cytotoxic T lymphocyte responses select for amino acid variation in simian immunodeficiency virus
34. The neutralising antibody response to HIV-1: Viral evasion and escape from humoral immunity
35. Selection for neutralisation resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation
36. Viral persistence in vivo through selection of neutralising antibody escape variants
37. Different effects of a single amino acid substitution on three adjacent epitopes in the gp41 C-terminal tail of a neutralising antibody escape mutant of human immunodeficiency virus type 1
38. Characterization of immune escape viruses from a macaque immunised with live-virus vaccine and challenged with pathogenic SHIVKU-1
39. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa
40. Identification of a complex env subtype E HIV type 1 virus from the Democratic Republic of Congo, recombinant with A, G, H, J, K, and unknown subtypes
41. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B′) recombinant strain in China
42. Skewed maturation of memory HIV-specific CD8 T lymphocytes
43. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
44. Viral dynamics in human immunodeficiency virus type 1 infection
45. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
46. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates
47. Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype
48. Chemokine receptors: Keys to AIDS pathogenesis?
49. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
50. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4
51. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
52. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
53. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC CKR5
54. Identification of a major co-receptor for primary isolates of HIV-1
55. In vivo HIV-1 infection of CD45RA(+) CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline
56. Differential co-receptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1
57. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates
58. Broader tropism and higher cytopathicity for CD4+ T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4+ T cell decline in vivo
59. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection
60. Fluctuations in steady state level of genomic HIV-1 RNA and replication intermediates related to disease progression rate
61. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS
62. A clinically relevant HIV-1 subunit vaccine protects Rhesus macaques from in vivo passaged simian/human immunodeficiency virus infection
63. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: Effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus HIV-1 chimeric virus
64. Neutralising antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunisations
65. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
66. HIV-1 envelope-elicited neutralising antibody titres correlate with protection and virus load in chimpanzees
67. Immunisation of chimpanzees confers protection against challenge with human immunodeficiency virus
68. Virus load in chimpanzees infected with human immunodeficiency virus type 1: Effect of pre-exposure vaccination
69. IgG surfaces as an important component in mucosal protection
70. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
71. Correlates of protective immunity against HIV-1 infection in immunised chimpanzees
72. The consequence of passive administration of an antihuman immunodeficiency virus type 1 neutralising monoclonal antibody before challenge of chimpanzees with a primary virus isolate
73. Prevention of HIV infection by passive immunisation with HIV immunoglobulin
74. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralising antibodies
75. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralising antibodies
76. Human neutralising monoclonal antibodies of the IgG1 subtype protect against mucosal simian/human immunodeficiency virus infection
77. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions
78. Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in Rhesus macaques: Robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain
79. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells
80. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques
81. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in Rhesus monkeys
82. Control of viremia and prevention of clinical AIDS in Rhesus monkeys by cytokine-augmented DNA vaccination
83. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
84. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: Compiled pre-clinical efficacy data from trials with 10 different HIV-1 vaccine candidates
85. The role of type-1 and type-2 T helper immune responses in HIV-1 vaccine protection
86. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance
87. Beta-chemokines and neutralising antibody titers correlate with sterilising immunity generated in HIV-1 vaccinated macaques
88. Protective mucosal immunity elicited by targeted iliac lymph node immunisation with a subunit SIV envelope and core vaccine in macaques
89. Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates
90. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
91. Immunisation with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production
92. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
93. Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated Rhesus monkeys detected using a peptide major histocompatibility complex class II tetramer
94. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected Rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I peptide complex
95. The role of non-human primates in the development of an AIDS vaccine
96. Human immunodeficiency virus type 1 challenge of chimpanzees immunised with recombinant envelope glycoprotein gp120
97. Challenge of chimpanzees (Pan troglodytes) immunised with human immunodeficiency virus envelope glycoprotein gp120
98. Immunisation with envelope subunit vaccine products elicits neutralising antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
99. Neutralisation of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines
100. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells
101. Resistance of chimpanzees immunised with recombinant gp120 SF2 to challenge by HIV-1 SF2
102. Protection of MN-rgp120-immunised chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
103. Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3
104. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines
105. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
106. Deceptive imprinting: A cosmopolitan strategy for complicating vaccination
107. AIDS epidemic at the beginning of the third millennium: Time for a new AIDS vaccine strategy
108. Adjuvanted vaccine strategies and live vector approaches for the prevention of AIDS
109. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais
110. Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus
111. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320
112. Functional and immunologic characterisation of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions
113. Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein
114. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB gp120 peptide RP135
115. A role for carbohydrates in immune evasion in AIDS
116. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralising antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
117. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
118. Anti-HIV env immunities elicited by nucleic acid vaccines
119. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunised Rhesus macaques
120. Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines
121. Antigen-specific humoral and cellular immune responses can be modulated in Rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants
122. Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine
123. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine
124. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration
125. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in Rhesus monkeys
126. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
127. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp160 envelope proteins
128. HIV-specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA
129. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA
130. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
131. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview
132. Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions
133. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine
134. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC
135. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B and T cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine
136. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner
137. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time- and dose-dependent: Suppressive effects of IL-12 boost are mediated by nitric oxide
138. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure
139. CD8+ lymphocyte antiviral activity in monkeys immunised with SIV recombinant poxvirus vaccines: Potential role in vaccine efficacy
140. In vitro and in vivo responses to interleukin-12 are maintained until the late SIV infection stage but lost during AIDS
141. Canarypox virus-mediated interleukin-12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity
142. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in Rhesus macaques and decreases viral burden following vaginal challenge
143. Factors associated with slow disease progression in macaques immunised with an adenovirus-simian immunodeficiency virus (SIV) envelope priming gp120 boosting regimen and challenged vaginally with SIVmac251
144. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration
145. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunisation
146. Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras
147. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus
148. Merck remerges with a bold vaccine effort
149. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
150. Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors
151. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
152. Outcome of immunisation of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
153. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
154. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
155. Enhancing immune responses using suicidal DNA vaccines
156. DNA immunisation against herpes simplex virus: Enhanced efficacy using a Sindbis virus-based vector
157. Herpes simplex viruses
158. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
159. Delivery systems and adjuvants for vaccination against HIV
160. Bacterial AIDS vaccine ready for testing
161. HIV gp120-specific cell-mediated immune responses in mice after oral immunisation with recombinant Salmonella
162. Immunisation of Macaca mulatta with aroA attenuated Salmonella typhimurium expressing the SIVp27 antigen
163. Potential live vaccines for HIV
164. Vaginal immunisation of cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens
165. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii
166. Successful primate immunisation with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants
167. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals
168. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 Env antigen induces neutralising antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs
169. Immunisation with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in Rhesus monkeys
170. Induction of human immunodeficiency virus (HIV)-specific CD8 T cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens
171. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes
172. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus
173. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells
174. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into Rhesus macaques
175. HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women
176. A rational basis for mucosal vaccination against HIV infection
177. Protection against vaginal SIV transmission with microencapsulated vaccine
178. Oral immunisation with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in non-human primates
179. Rectal and vaginal immunisation with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses
180. Intranasal immunisation with HIV reverse transcriptase: Effect of dose in the induction of helper T cell type 1 and 2 immunity
181. Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates
182. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
183. Prime-boost immunisation strategies against HIV
184. Canarypox virus-based vaccines: Prime-boost strategies to induce cell-mediated and humoral immunity against HIV
185. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
186. Recombinant subunit vaccines against primate lentiviruses
187. Gene gun-based nucleic acid immunisation alone or in combination with recombinant vaccinia vectors suppresses virus burden in Rhesus macaques challenged with a heterologous SIV
188. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunisation with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1 SF2 recombinant gp120
189. A human immunodeficiency virus prime-boost immunisation regimen in humans induces antibodies that show interclade cross-reactivity and neutralise several X4-, R5-, and dualtropic clade B and C primary isolates
190. Cytokine profiles in seronegative volunteers immunised with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group
191. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
192. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from Rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
193. Pre-clinical development of a multiCTL epitope-based DNA prime MVA boost vaccine for AIDS
194. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA Vaccine
195. A vaccine strategy utilising a combination of three different chimeric vectors which share specific vaccine antigens
196. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
197. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
198. Live attenuated, multiple deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
199. HIV accessory proteins as therapeutic targets
200. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
201. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunisation followed by highly active antiretroviral treatment
202. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes
203. Vaccination with Rev and Tat against AIDS
204. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
205. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
206. Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus
207. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
208. Generation of HIV latency during thymopoiesis
209. Change in co-receptor use co-receptor use correlates with disease progression in HIV-1-infected individuals
210. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells
211. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain
212. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes
213. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells
214. The effect of HIV-1 regulatory proteins on cellular genes: Derepression of the IL-2 promoter by Tat
215. Apoptosis in AIDS